Skip to main content
. Author manuscript; available in PMC: 2017 Jun 22.
Published in final edited form as: Lab Invest. 2016 Aug 29;96(11):1147–1155. doi: 10.1038/labinvest.2016.93

Figure 4.

Figure 4

Evaluation of cholangiocyte proliferation with the administration of vasopressin (0.1–100 μg/ml) at different concentrations for 24 h by MTT assay in mice small and large cholangiocytes (a); in small cholangiocytes with the preincubation with two V2 antagonists: Tolvaptan and OPC-31260 (b); and in H69 and LCDE (c). Vasopressin increased growth of small cholangiocytes, H69 and LCDE in a dose-dependent manner, while large cholangiocytes are not sensitive to these concentrations of the hormone. The proliferation was also partly inhibited by the two V2 antagonists. *P<0.05 vs basal treatment, #P<0.05 vs AVP 100 μg treatment. Data are means ± s.e. of five experiments.